Monitoring blood levels of microRNAs in patients with grade 4 gliomas
Official title: Monitoring of Patients With Diffuse Gliomas Using Circulating miRNAs
Run by University Hospital, Caen · NCT06203496 · Data updated 2026-11-12
This study is trying to see if tracking certain microRNAs in the blood can help tell the difference between tumor recurrence and tissue damage in patients with grade 4 gliomas after surgery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | University Hospital, Caen Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Caen) |
| Status | Recruiting |
| Started | January 1, 2024 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | January 12, 2024 |
| Trial ID | NCT06203496 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adult patients diagnosed with grade 4 diffuse glioma who have undergone surgical treatment at Caen University Hospital.
✕Probably not a fit
Patients with lower-grade gliomas or those who have undergone biopsy instead of surgical excision may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to track the changes in plasma levels of pro-oncogenic microRNAs in patients who have undergone surgery for grade 4 diffuse gliomas. By analyzing blood samples over time, the study seeks to determine if these microRNAs can serve as reliable biomarkers to differentiate between tumor recurrence and radionecrosis. The research is motivated by previous findings that suggest a correlation between serum microRNA levels and tumor progression in gliomas. The study will involve patients treated at Caen University Hospital, ensuring a homogeneous sample for analysis.
Why it matters
Potential benefit: If successful, this study could provide a non-invasive method for monitoring glioma recurrence, potentially improving patient management and outcomes.
How similar studies have gone: While preliminary studies have shown promise in using microRNAs as biomarkers for gliomas, this approach is still being validated and is not yet widely established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Major patient * Grade 4 diffuse glioma * Surgery in the neurosurgery department of Caen University Hospital * Patient affiliated to a social security scheme * Patient followed at Caen University Hospital * No opposition from patient Exclusion Criteria: * \- Patients who underwent biopsy (lack of material for study, limited interest of monitoring for these patients without surgical excision). * Patients with grade 1 circumscribed glioma or grade 2 or 3 diffuse glioma. * Other non-glial histologies, glioneuronal histology * Minor patients * Patient not affiliated to a social security scheme * A minor under guardianship or protection * Patient opposed to study
Where it's running
-
Arthur Leclerc
Caen, France Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
LMP744 (an indenoisoquinolone) for people with recurrent glioblastoma
This trial will test whether the drug LMP744 can shrink tumors or slow progression in adults whose glioblastoma has returned after prior treatment.
-
C5252 injection for intracranial glioma
A phase I/IIa study tests C5252 given into the brain to see if it is safe and whether it helps people with recurrent malignant glioma after standard therapies.
-
Using 18F-TRX to image solid tumors
This trial tests whether the 18F-TRX PET tracer can detect tumors in adults with advanced solid tumors such as high‑grade glioma, clear cell renal cell carcinoma, or metastatic castration‑resistant prostate cancer.
-
Testing TNG456 and Abemaciclib in Patients with Solid Tumors Lacking MTAP
This study is testing a new drug called TNG456, alone and with another drug called abemaciclib, to see if it helps people with advanced solid tumors that have lost a specific gene called MTAP.
-
Testing DSP-0390 in patients with IDH-mutant gliomas
This study is testing a new drug called DSP-0390 in patients with specific types of brain tumors to see if it helps kill more tumor cells during surgery.
-
Cognitive rehabilitation program for patients with diffuse glioma
This study is testing a new online brain training program to see if it can help people with diffuse glioma improve their memory and thinking skills after treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.